Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs Cytotoxic Reviews Godefridus J. Peters and Eric Raymond

Research output: Contribution to journalReview article

71 Citations (Scopus)

Abstract

The presence of a microenvironment within most tumours containing regions of low oxygen tension or hypoxia has profound biological and therapeutic implications. Tumour hypoxia is known to promote the development of an aggressive phenotype, resistance to both chemotherapy and radiotherapy and is strongly associated with poor clinical outcome. Paradoxically, it is recognised as a high-priority target and one of the therapeutic strategies designed to eradicate hypoxic cells in tumours is a group of compounds known collectively as hypoxia-activated prodrugs (HAPs) or bioreductive drugs. These drugs are inactive prodrugs that require enzymatic activation (typically by 1 or 2 electron oxidoreductases) to generate cytotoxic species with selectivity for hypoxic cells being determined by (1) the ability of oxygen to either reverse or inhibit the activation process and (2) the presence of elevated expression of oxidoreductases in tumours. The concepts underpinning HAP development were established over 40 years ago and have been refined over the years to produce a new generation of HAPs that are under preclinical and clinical development. The purpose of this article is to describe current progress in the development of HAPs focusing on the mechanisms of action, preclinical properties and clinical progress of leading examples.

LanguageEnglish
Pages441-457
Number of pages17
JournalCancer Chemotherapy and Pharmacology
Volume77
Issue number3
DOIs
Publication statusPublished - 1 Mar 2016

Fingerprint

Prodrugs
Tumors
Oxidoreductases
Chemical activation
Cells
Oxygen
Neoplasms
Chemotherapy
Radiotherapy
Pharmaceutical Preparations
Tumor Hypoxia
Hypoxia
Electrons
Phenotype
Drug Therapy
Therapeutics

Cite this

@article{5da1cda1925c49cf93a26f64a9814375,
title = "Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs Cytotoxic Reviews Godefridus J. Peters and Eric Raymond",
abstract = "The presence of a microenvironment within most tumours containing regions of low oxygen tension or hypoxia has profound biological and therapeutic implications. Tumour hypoxia is known to promote the development of an aggressive phenotype, resistance to both chemotherapy and radiotherapy and is strongly associated with poor clinical outcome. Paradoxically, it is recognised as a high-priority target and one of the therapeutic strategies designed to eradicate hypoxic cells in tumours is a group of compounds known collectively as hypoxia-activated prodrugs (HAPs) or bioreductive drugs. These drugs are inactive prodrugs that require enzymatic activation (typically by 1 or 2 electron oxidoreductases) to generate cytotoxic species with selectivity for hypoxic cells being determined by (1) the ability of oxygen to either reverse or inhibit the activation process and (2) the presence of elevated expression of oxidoreductases in tumours. The concepts underpinning HAP development were established over 40 years ago and have been refined over the years to produce a new generation of HAPs that are under preclinical and clinical development. The purpose of this article is to describe current progress in the development of HAPs focusing on the mechanisms of action, preclinical properties and clinical progress of leading examples.",
keywords = "AQ4N, Bioreductive drugs, EO9, Hypoxia, Hypoxia-activated prodrugs, PR-104, TH-302, TH-4000, Tirapazamine",
author = "Phillips, {Roger M.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00280-015-2920-7",
language = "English",
volume = "77",
pages = "441--457",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs Cytotoxic Reviews Godefridus J. Peters and Eric Raymond

AU - Phillips, Roger M.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The presence of a microenvironment within most tumours containing regions of low oxygen tension or hypoxia has profound biological and therapeutic implications. Tumour hypoxia is known to promote the development of an aggressive phenotype, resistance to both chemotherapy and radiotherapy and is strongly associated with poor clinical outcome. Paradoxically, it is recognised as a high-priority target and one of the therapeutic strategies designed to eradicate hypoxic cells in tumours is a group of compounds known collectively as hypoxia-activated prodrugs (HAPs) or bioreductive drugs. These drugs are inactive prodrugs that require enzymatic activation (typically by 1 or 2 electron oxidoreductases) to generate cytotoxic species with selectivity for hypoxic cells being determined by (1) the ability of oxygen to either reverse or inhibit the activation process and (2) the presence of elevated expression of oxidoreductases in tumours. The concepts underpinning HAP development were established over 40 years ago and have been refined over the years to produce a new generation of HAPs that are under preclinical and clinical development. The purpose of this article is to describe current progress in the development of HAPs focusing on the mechanisms of action, preclinical properties and clinical progress of leading examples.

AB - The presence of a microenvironment within most tumours containing regions of low oxygen tension or hypoxia has profound biological and therapeutic implications. Tumour hypoxia is known to promote the development of an aggressive phenotype, resistance to both chemotherapy and radiotherapy and is strongly associated with poor clinical outcome. Paradoxically, it is recognised as a high-priority target and one of the therapeutic strategies designed to eradicate hypoxic cells in tumours is a group of compounds known collectively as hypoxia-activated prodrugs (HAPs) or bioreductive drugs. These drugs are inactive prodrugs that require enzymatic activation (typically by 1 or 2 electron oxidoreductases) to generate cytotoxic species with selectivity for hypoxic cells being determined by (1) the ability of oxygen to either reverse or inhibit the activation process and (2) the presence of elevated expression of oxidoreductases in tumours. The concepts underpinning HAP development were established over 40 years ago and have been refined over the years to produce a new generation of HAPs that are under preclinical and clinical development. The purpose of this article is to describe current progress in the development of HAPs focusing on the mechanisms of action, preclinical properties and clinical progress of leading examples.

KW - AQ4N

KW - Bioreductive drugs

KW - EO9

KW - Hypoxia

KW - Hypoxia-activated prodrugs

KW - PR-104

KW - TH-302

KW - TH-4000

KW - Tirapazamine

UR - http://www.scopus.com/inward/record.url?scp=84959507403&partnerID=8YFLogxK

U2 - 10.1007/s00280-015-2920-7

DO - 10.1007/s00280-015-2920-7

M3 - Review article

VL - 77

SP - 441

EP - 457

JO - Cancer Chemotherapy and Pharmacology

T2 - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -